289 related articles for article (PubMed ID: 20929960)
1. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease.
Blázquez C; Chiarlone A; Sagredo O; Aguado T; Pazos MR; Resel E; Palazuelos J; Julien B; Salazar M; Börner C; Benito C; Carrasco C; Diez-Zaera M; Paoletti P; Díaz-Hernández M; Ruiz C; Sendtner M; Lucas JJ; de Yébenes JG; Marsicano G; Monory K; Lutz B; Romero J; Alberch J; Ginés S; Kraus J; Fernández-Ruiz J; Galve-Roperh I; Guzmán M
Brain; 2011 Jan; 134(Pt 1):119-36. PubMed ID: 20929960
[TBL] [Abstract][Full Text] [Related]
2. Worsening of Huntington disease phenotype in CB1 receptor knockout mice.
Mievis S; Blum D; Ledent C
Neurobiol Dis; 2011 Jun; 42(3):524-9. PubMed ID: 21406230
[TBL] [Abstract][Full Text] [Related]
3. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity.
Palazuelos J; Aguado T; Pazos MR; Julien B; Carrasco C; Resel E; Sagredo O; Benito C; Romero J; Azcoitia I; Fernández-Ruiz J; Guzmán M; Galve-Roperh I
Brain; 2009 Nov; 132(Pt 11):3152-64. PubMed ID: 19805493
[TBL] [Abstract][Full Text] [Related]
4. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.
Dowie MJ; Bradshaw HB; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
Neuroscience; 2009 Sep; 163(1):456-65. PubMed ID: 19524019
[TBL] [Abstract][Full Text] [Related]
5. Ex vivo delivery of GDNF maintains motor function and prevents neuronal loss in a transgenic mouse model of Huntington's disease.
Ebert AD; Barber AE; Heins BM; Svendsen CN
Exp Neurol; 2010 Jul; 224(1):155-62. PubMed ID: 20227407
[TBL] [Abstract][Full Text] [Related]
6. Cortical expression of brain derived neurotrophic factor and type-1 cannabinoid receptor after striatal excitotoxic lesions.
De March Z; Zuccato C; Giampà C; Patassini S; Bari M; Gasperi V; De Ceballos ML; Bernardi G; Maccarrone M; Cattaneo E; Fusco FR
Neuroscience; 2008 Mar; 152(3):734-40. PubMed ID: 18313855
[TBL] [Abstract][Full Text] [Related]
7. Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice.
Denovan-Wright EM; Robertson HA
Neuroscience; 2000; 98(4):705-13. PubMed ID: 10891614
[TBL] [Abstract][Full Text] [Related]
8. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.
Lastres-Becker I; Hansen HH; Berrendero F; De Miguel R; Pérez-Rosado A; Manzanares J; Ramos JA; Fernández-Ruiz J
Synapse; 2002 Apr; 44(1):23-35. PubMed ID: 11842443
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoid (CB(1)), GABA(A) and GABA(B) receptor subunit changes in the globus pallidus in Huntington's disease.
Allen KL; Waldvogel HJ; Glass M; Faull RL
J Chem Neuroanat; 2009 Jul; 37(4):266-81. PubMed ID: 19481011
[TBL] [Abstract][Full Text] [Related]
10. Excitotoxic brain damage involves early peroxynitrite formation in a model of Huntington's disease in rats: protective role of iron porphyrinate 5,10,15,20-tetrakis (4-sulfonatophenyl)porphyrinate iron (III).
Pérez-De La Cruz V; González-Cortés C; Galván-Arzate S; Medina-Campos ON; Pérez-Severiano F; Ali SF; Pedraza-Chaverrí J; Santamaría A
Neuroscience; 2005; 135(2):463-74. PubMed ID: 16111817
[TBL] [Abstract][Full Text] [Related]
11. Selective vulnerability in Huntington's disease: preferential loss of cannabinoid receptors in lateral globus pallidus.
Richfield EK; Herkenham M
Ann Neurol; 1994 Oct; 36(4):577-84. PubMed ID: 7944290
[TBL] [Abstract][Full Text] [Related]
12. Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease.
Emerich DF; Winn SR; Hantraye PM; Peschanski M; Chen EY; Chu Y; McDermott P; Baetge EE; Kordower JH
Nature; 1997 Mar; 386(6623):395-9. PubMed ID: 9121555
[TBL] [Abstract][Full Text] [Related]
13. Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice.
McCaw EA; Hu H; Gomez GT; Hebb AL; Kelly ME; Denovan-Wright EM
Eur J Biochem; 2004 Dec; 271(23-24):4909-20. PubMed ID: 15606779
[TBL] [Abstract][Full Text] [Related]
14. Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease.
Desplats PA; Kass KE; Gilmartin T; Stanwood GD; Woodward EL; Head SR; Sutcliffe JG; Thomas EA
J Neurochem; 2006 Feb; 96(3):743-57. PubMed ID: 16405510
[TBL] [Abstract][Full Text] [Related]
15. A novel population of progenitor cells expressing cannabinoid receptors in the subependymal layer of the adult normal and Huntington's disease human brain.
Curtis MA; Faull RL; Glass M
J Chem Neuroanat; 2006 Apr; 31(3):210-5. PubMed ID: 16533591
[TBL] [Abstract][Full Text] [Related]
16. Glutamate toxicity in the striatum of the R6/2 Huntington's disease transgenic mice is age-dependent and correlates with decreased levels of glutamate transporters.
Estrada-Sánchez AM; Montiel T; Segovia J; Massieu L
Neurobiol Dis; 2009 Apr; 34(1):78-86. PubMed ID: 19168136
[TBL] [Abstract][Full Text] [Related]
17. Sustained striatal ciliary neurotrophic factor expression negatively affects behavior and gene expression in normal and R6/1 mice.
Denovan-Wright EM; Attis M; Rodriguez-Lebron E; Mandel RJ
J Neurosci Res; 2008 Jun; 86(8):1748-57. PubMed ID: 18293418
[TBL] [Abstract][Full Text] [Related]
18. Activation of Elk-1 participates as a neuroprotective compensatory mechanism in models of Huntington's disease.
Anglada-Huguet M; Giralt A; Perez-Navarro E; Alberch J; Xifró X
J Neurochem; 2012 May; 121(4):639-48. PubMed ID: 22372926
[TBL] [Abstract][Full Text] [Related]
19. Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6/2 mouse model of Huntington's disease.
Giampà C; Middei S; Patassini S; Borreca A; Marullo F; Laurenti D; Bernardi G; Ammassari-Teule M; Fusco FR
Eur J Neurosci; 2009 Mar; 29(5):902-10. PubMed ID: 19291221
[TBL] [Abstract][Full Text] [Related]
20. Cell type-specific localization of optineurin in the striatal neurons of mice: implications for neuronal vulnerability in Huntington's disease.
Okita S; Morigaki R; Koizumi H; Kaji R; Nagahiro S; Goto S
Neuroscience; 2012 Jan; 202():363-70. PubMed ID: 22155493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
